Exploring Common CDISC ADaM Conformance Findings Blog Exploring Common CDISC ADaM Conformance Findings 2025年3月27日 ADaM data are required by the FDA and PMDA and accepted by…Certara2025年3月27日
FDA Requirements for Providing Datasets for Nonclinical Studies in SEND Format Blog FDA Requirements for Providing Datasets for Nonclinical Studies in SEND Format 2025年3月19日 The CDISC Standard for the Exchange of Nonclinical Data (SEND) provides the…Certara2025年3月19日
Rolling NDA and BLA Submissions: Accelerate Your Review Timeline Blog NDA および BLA の段階的申請:Accelerate Your Review Timeline We look at the growing regulatory trend of rolling NDA and BLA submissions to help…Certara2025年2月3日
GlobalSubmit eCTD 4.0 Webinars On-Demand Webinar GlobalSubmit eCTD 4.0 ウェビナー The world of electronic regulatory submissions is about to change with the introduction of eCTD…Certara2024年12月3日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Certara2024年11月22日
Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis. ポスター Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis. Certara2024年11月22日
Clinical Metadata Standardization: Evaluating the Importance of a Metadata Repository in Clinical Trials White Paper Clinical Metadata Standardization: Evaluating the Importance of a Metadata Repository in Clinical Trials Whether you’re considering a metadata repository or want to learn about clinical metadata standardization, our…Certara2024年11月22日
Building Automated Pharmacometrics Analysis Workflows in R with NMsim Poster Building Automated Pharmacometrics Analysis Workflows in R with NMsim Certara2024年11月22日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Certara2024年11月22日
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Poster Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Certara2024年11月22日